Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Gene Therapy for Hemophilia A Associated With Sustained Reductions in Bleeding Rates

Publish date:: August 7, 2019

Key clinical point: Gene therapy for hemophilia A appears to be associated with sustained reductions in bleeding rates.

Major finding: Bleeding rates were reduced by 96% in the 6 x 10¹³ vg/kg group by year 3 with the gene therapy.

Study details: Phase 1/2 trial in 15 adults with hemophilia A who received valoctocogene roxaparvovec.

Disclosures: The study was sponsored by manufacturer BioMarin Pharmaceutical. Dr. Pasi reported financial relationships with the study sponsor and other companies.

Citation:

Pasi KJ et al. 2019 ISTH Congress, Abstract LB 01.2.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Annual WCC visits significantly limit asthma worsening,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Microplastics permeate human placentas,

Must Reads in Hematology

Emotions, worse attention linked to pain-related health care use SCD,

Mouth splints decrease risk of post–dental extraction bleeding in hemophilia,

Large cohort study: Bevacizumab safe, effective for severe HHT bleeds,

SPK-8011 AAV-mediated Hemophilia A therapy shows stability, durability,

Heavy menstrual bleeding difficult to control in young patients with inherited platelet disorders,